Full Press Release Details
WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences:
Event: Jefferies Global Healthcare Conference – New York
Date: Wednesday, June 3, 2026
Fireside Time: 12:15 pm ET
Event: Goldman Sachs 47th Annual Global Healthcare Conference – Miami
Date: Monday, June 8, 2026
Fireside Time: 10:00 am ET
Members of the Spyre management team will also host one-on-one investor meetings during the conferences.
Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.
For more information, visit Spyre's website at www.spyre.com.
Eric McIntyre, Spyre Therapeutics
SVP of Finance and Investor Relations